South Korea Japan Singapore Usa Mexico state Nebraska hospital covid-19 patient South Korea Japan Singapore Usa Mexico state Nebraska

Trials find no benefit of interferon, colchicine in COVID hospital patients

Reading now: 478
www.cidrap.umn.edu

New clinical trials detail the failure of two COVID-19 treatments—a combination of interferon beta-1a and remdesivir and the drug colchicine—to reduce death by 28 days, length of hospital stay, or risk of requiring invasive mechanical ventilation or dying in hospitalized adults.Both trials were published yesterday in The Lancet Respiratory Medicine.More adverse events with interferon beta-1aIn a phase 3 clinical trial sponsored by the National Institute of Allergy and Infectious Diseases, a team led by a University of Nebraska researcher randomly assigned 969 COVID-19 patients admitted to 63 hospitals in five countries (Japan, Mexico, Singapore, South Korea, and the United States) in a 1:1 ratio to receive either interferon beta-1a plus

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA